SCHEMBL1747259

SCHEMBL1747259

COC(=O)CCc1ccc(OCc2ccc(CN(C)c3nc(-c4ccccc4)c(C)s3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
FFAR1 O14842 9/20 0.45
PPARD Q03181 4/20 0.45
VDR P11473 2/20 0.45
PPARG P37231 2/20 0.44
FFAR4 Q5NUL3 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
PPARA Q07869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746854 0.92 FFAR1 (0.56) MEN1KMT2ALMNAPOLBPKM
SCHEMBL1745514 0.89 PPARD (0.46) MEN1KMT2ALMNAPOLBPKM
SCHEMBL12628114 0.84 MEN1 (0.41) MEN1KMT2ALMNAPOLBPKM
SCHEMBL2003964 0.83 ALDH1A1 (0.49) MEN1KMT2AFFAR1PPARDVDR
SCHEMBL1746563 0.83 KMT2A (0.49) MEN1KMT2ANPSR1FFAR1PPARD
SCHEMBL1746828 0.82 FFAR1 (0.56) FFAR1PPARDPPARGFFAR4PPARA
SCHEMBL1744702 0.80 PPARD (0.54) FFAR1PPARDPPARGFFAR4PPARA
SCHEMBL5402205 0.79 FFAR1 (0.56) FFAR1PPARGMAPTPPARA
SCHEMBL1745408 0.79 FFAR1 (0.54) FFAR1PPARGFFAR4ALDH1A1PPARA
SCHEMBL1996932 0.79 VDR (0.49) MEN1KMT2AFFAR1PPARDVDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MEN1 2579/4885KMT2A 4408/4885LMNA 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.